Retagliptin

Drug Profile

Retagliptin

Alternative Names: SP 2086

Latest Information Update: 05 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antihyperglycaemics; Carboxylic acids; Fluorobenzenes; Imidazoles; Pyrazines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Jul 2016 Jiangsu HengRui Medicine Co. plans a phase I pharmacokinetics trial in Healthy volunteers in China (PO) (NCT02826044)
  • 01 Apr 2016 Jiangsu HengRui Medicine Co. initiates a phase I pharmacokinetics trial for Type-2 diabetes mellitus in China (PO) (NCT02822534)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top